Methyl 4-Bromo-2-Thiazole Carboxylate

In a 500 L glass-lined reactor operated under nitrogen blanketing at a jacket temperature of -5°C to 0°C, the lithiation of Methyl 4-Bromo-2-Thiazole Carboxylate with 2.5 M n-butyllithium in anhydrous THF proceeds regioselectively at the C-5 position, affording a nucleophilic species that can be quenched with trimethyl borate to yield the corresponding boronic acid derivative. This transformation underpins the compound's role as a critical progenitor in the synthesis of FLT3 kinase inhibitors, a class of targeted oncology therapeutics. The bromine atom at C-4 remains intact during this sequence, preserving a second reactive handle for downstream diversification via palladium-mediated cross-coupling. Industrial execution of this chemistry demands rigorous exclusion of protic contaminants: residual moisture in the THF solvent must not exceed 50 ppm as determined by Karl Fischer titration (ASTM E203-16), and the dew point of the reactor headspace nitrogen is maintained below -40°C. The molar stoichiometry of n-BuLi to substrate is tightly controlled at 1.02:1.00; excursions beyond 1.05 equivalents initiate competing deprotonation at C-2, generating a ketene-imine intermediate that degrades to intractable tars and reduces isolated yield by 18-25%. Following the boronation quench, the crude boronic acid intermediate is telescoped directly into a Suzuki-Miyaura coupling with a substituted 2-aminopyrimidine fragment, employing Pd(dppf)Cl₂·CH₂Cl₂ at a catalyst loading of 0.8 mol% in a biphasic toluene/ 2M aqueous K₃PO₄ system. The coupling step achieves >96% conversion by HPLC area percent within 4 hours at 80°C internal temperature. The resulting biaryl thiazole scaffold is subsequently elaborated through carboxamide formation at the C-2 ester moiety, utilizing a 1.3:1 molar ratio of the amine coupling partner in the presence of 2.0 equivalents of trimethylaluminum as a Lewis acid activator in toluene at 60°C, generating the final FLT3 inhibitor pharmacophore. The FDA guidance for the residual palladium limit in the finished API is governed by ICH Q3D Guideline for Elemental Impurities, Table A.2.2, specifying a permitted daily exposure (PDE) of 100 µg/day for oral administration and 10 µg/day for parenteral routes, necessitating an upstream purification sequence comprising activated carbon treatment (Darco G-60, 5 wt% relative to crude product mass), hot filtration through a 0.45 µm PTFE membrane, and final recrystallization from isopropanol/water (70:30 v/v) to achieve residual Pd levels consistently below 5 ppm. Production-scale batch records document a crystallization-induced diastereomeric enrichment effect: slow cooling from 65°C to 20°C over 8 hours with a ramp rate of 0.09°C/min increases the enantiomeric excess of the desired atropisomer from 82% to 99.4%, a process window that is lost entirely if the cooling rate exceeds 0.15°C/min. Equipment limitations become critically apparent at this stage; use of a standard half-pipe coil jacket on a 500 L vessel cannot deliver a controlled ramp below 0.12°C/min, necessitating a split-range cascade control strategy with an external plate heat exchanger recirculation loop. The terminal drug product formulated from this intermediate is an oral immediate-release tablet containing the FLT3 inhibitor as the besylate salt at a dose strength of 40 mg or 80 mg, manufactured via direct compression with microcrystalline cellulose (Avicel PH-102, 47.5 wt%), mannitol (25.0 wt%), croscarmellose sodium (4.0 wt%), colloidal silicon dioxide (1.5 wt%), and magnesium stearate (1.0 wt%) as an extragranular lubricant, with tablet hardness controlled to 8-12 kp (USP <1217>, Tablet Breaking Force).

How Does the 4-Bromo Substituent Influence Reactivity in Agrochemical Intermediate Synthesis?

Methyl 4-Bromo-2-Thiazole Carboxylate enters the agrochemical supply chain as a versatile progenitor of succinate dehydrogenase inhibitor (SDHI) fungicide intermediates bearing the 2-thiazolecarboxamide pharmacophore. The synthetic sequence capitalizes on the orthogonal reactivity of the C-2 ester and the C-4 bromide: the ester undergoes direct aminolysis with 1.05-1.15 equivalents of a primary amine (typically 2-(1,3-dimethylbutyl)aniline or its structural congeners) in refluxing toluene, facilitated by 0.5 equivalents of DABCO as a nucleophilic catalyst, to install the signature carboxamide motif. This step proceeds to >97% conversion as monitored by in situ FTIR tracking of the ester carbonyl stretch at 1726 cm⁻¹; the signal diminishes with a half-life of 32 minutes at 110°C reflux. The residual C-4 bromide of the resultant amide intermediate then serves as the locus for a second diversification event—typically a Buchwald-Hartwig amination employing benzophenone imine as an ammonia surrogate, Pd₂(dba)₃ (1.2 mol% Pd), rac-BINAP (2.4 mol%), and sodium tert-butoxide (1.4 equivalents) in toluene at 85°C. The imine adduct is cleaved under mild acidic conditions (1N HCl in THF/water) to unmask the free C-4 amine, which is then acylated with a substituted benzoyl chloride to complete the SDHI framework. Throughout the sequence, the molar mass balance is tightly tracked: the theoretical mass efficiency (TME) for the three-step telescoped process from Methyl 4-Bromo-2-Thiazole Carboxylate to the final SDHI intermediate is 0.48 kg/kg, with the primary mass loss occurring at the imine deprotection step (liberation of benzophenone, 182 g/mol). Compliance with FAO specifications for pesticide manufacturing (FAO Manual on Development and Use of FAO Specifications for Plant Protection Products, 5th Edition, Section 3.5) mandates that any individual unspecified impurity in the technical-grade intermediate remain below 0.5% peak area by GC-FID, requiring a minimum of 5 theoretical plates in the final high-vacuum fractional distillation step. Operational reality on a 200 L wiped-film evaporator (Pope Scientific, 0.02 m² evaporator surface, rotor speed 350 rpm) introduces a processing bottleneck: the viscosity of the crude product mixture at 60°C approaches 850 cP, which exceeds the recommended maximum of 500 cP for continuous thin-film operation without fouling. Dilution with 15 wt% of a low-boiling co-solvent (n-heptane, bp 98°C) reduces the feed viscosity to 320 cP and restores a stable film thickness of 0.25 mm on the evaporator wall, albeit at the cost of an additional 50 L/hr solvent recovery throughput on the downstream condenser. The formulated end-use product is a suspension concentrate (SC) containing the SDHI active ingredient at 200 g/L, stabilized with a styrene-acrylic graft copolymer dispersant (Atlox 4913, 30 g/L), a xanthan gum rheology modifier (Rhodopol 23, 2.5 g/L), and a biocide package (1,2-benzisothiazolin-3-one, 0.15 g/L), wet-milled to a particle size D₉₀ of 4.0 µm (Malvern Mastersizer 3000, laser diffraction, Mie theory parameters: real refractive index 1.59, absorption index 0.01).

In the context of coordination polymer and metal-organic framework (MOF) synthesis, Methyl 4-Bromo-2-Thiazole Carboxylate functions not as a stoichiometric synthetic intermediate but as a ligand precursor that is deliberately not isolated in its fully elaborated form prior to framework assembly. The target ligand—typically 4-(1H-tetrazol-5-yl)-2-thiazolecarboxylic acid or its 4-(carboxyl)-substituted analog—is generated in a two-step telescoped sequence followed by immediate complexation: the C-4 bromide undergoes a Rosenmund-von Braun cyanation with CuCN (1.2 equivalents) in DMF at 150°C to install a nitrile group, which is then converted to the tetrazole via [3+2] cycloaddition with sodium azide (1.5 equivalents) and zinc bromide (0.3 equivalents) in water at 100°C over 18 hours. The ester saponification at C-2 is effected with 2.5 equivalents of LiOH in THF/water (3:1 v/v) and is intentionally conducted after the tetrazole formation to avoid coordination of the carboxylate to copper during the cyanation step. The fully deprotected ditopic ligand—possessing both a carboxylate donor at C-2 and a tetrazolate donor at C-4—is then directly combined with ZrCl₄ in a 2:1 ligand-to-metal molar ratio in DMF containing 30 equivalents of formic acid as a modulating agent, yielding a UiO-67 analog with thiazole-tetrazolate mixed-linker functionality after solvothermal treatment at 120°C for 24 hours. The bromine content of the starting Methyl 4-Bromo-2-Thiazole Carboxylate (35.9 wt% Br) introduces a critical elemental purity requirement: residual bromide ion in the final MOF material, as quantified by combustion ion chromatography (EN 14582:2016), must not surpass 100 ppm for the material to meet the performance threshold for selective CO₂ adsorption over N₂ (selectivity factor >35 at 298 K and 1 bar). Washing the as-synthesized framework with methanol via Soxhlet extraction for 72 hours reduces residual halide to 48 ppm, which is acceptable for gas separation applications. The BET surface area, determined by nitrogen physisorption at 77 K (ISO 9277:2010, multipoint method over relative pressure range P/P₀ = 0.05-0.30), typically falls within 1150-1280 m²/g for batch sizes up to 50 grams; attempts to scale the solvothermal synthesis beyond 200 grams per batch in a 5 L Teflon-lined autoclave produce a bimodal pore size distribution with a secondary population of mesopores at 4.8 nm, attributed to incomplete formic acid modulation at the lower surface-area-to-volume ratio, and result in BET values declining to 780-920 m²/g. The terminal application of this MOF material is as a stationary phase component in a pressure-swing adsorption (PSA) skid for post-combustion flue gas CO₂ capture, operating at a cycle time of 240 seconds with a feed pressure of 6 bar and a regeneration vacuum of 0.1 bar.

Antimicrobial Drug Candidate Assembly Using Methyl 4-Bromo-2-Thiazole Carboxylate as a 2,4-Disubstituted Thiazole Template

The emergence of metallo-β-lactamase (MBL)-producing Gram-negative pathogens has revitalized medicinal chemistry interest in thiazole-based non-β-lactam antibacterials, wherein Methyl 4-Bromo-2-Thiazole Carboxylate provides a densely functionalized entry point into the 2,4-disubstituted thiazole chemical space. A documented synthetic pathway begins with the sodium borohydride reduction of the C-2 ester to the corresponding primary alcohol, employing 2.5 equivalents of NaBH₄ in a mixed solvent system of THF and methanol (4:1 v/v) at 0°C to room temperature over 6 hours, achieving 91% isolated yield after aqueous workup and silica gel chromatography (eluent: hexane:ethyl acetate, 3:2). The resultant hydroxymethyl intermediate is then activated as the methanesulfonate ester (MsCl, 1.1 equivalents, Et₃N 1.5 equivalents, CH₂Cl₂, 0°C, 45 minutes) and displaced with sodium azide (2.0 equivalents, DMF, 60°C, 4 hours) to install the azidomethyl moiety at C-2. The C-4 bromide is subjected to a copper-catalyzed azide-alkyne cycloaddition (CuAAC) in a one-pot sequence with a terminal alkyne-functionalized oxazolidinone fragment—the latter being a linezolid-derived pharmacophore—employing CuSO₄·5H₂O (0.1 equivalents) and sodium ascorbate (0.3 equivalents) in a tert-butanol:water (1:1) solvent system at 40°C. This click chemistry approach generates the 1,4-disubstituted 1,2,3-triazole linker tethering the thiazole core to the oxazolidinone antibacterial warhead with a regioisomeric purity >99% as determined by ¹H NMR integration of the triazole C-5 proton (δ 7.88 ppm in DMSO-d₆). The C-2 azidomethyl group is then reduced to the aminomethyl derivative via Staudinger reduction (PPh₃, 1.2 equivalents, THF:H₂O 10:1, 25°C, 12 hours), followed by acylation with 2,5-dichlorothiophene-3-carbonyl chloride to install the terminal heteroaromatic amide. The entire six-step sequence from Methyl 4-Bromo-2-Thiazole Carboxylate to the final antibacterial candidate proceeds with an overall yield of 42% and has been executed on 300-gram scale in a non-GMP kilo lab setting. A critical processing note pertains to the CuAAC step: dissolved oxygen in the solvent mixture must be reduced to < 0.5 mg/L via argon sparging for 30 minutes prior to catalyst addition, as the presence of O₂ re-oxidizes Cu(I) to Cu(II), slowing the catalytic cycle and promoting the formation of the undesired 1,5-disubstituted triazole regioisomer. The terminal product is a hydrochloride salt formulated as a lyophilized powder for reconstitution intended for intravenous infusion at a dose equivalent to 600 mg of the free base administered every 12 hours, targeting complicated skin and skin-structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). Antimicrobial susceptibility testing against a panel of 120 clinical MRSA isolates yielded MIC₉₀ values of 2 µg/mL, compared to 4 µg/mL for linezolid under identical CLSI broth microdilution conditions (M07-A10). The impurity profile of the drug substance intermediate is governed by ICH Q3A (R2): any individual unspecified impurity exceeding the identification threshold of 0.10% must be structurally characterized by LC-HRMS and its genotoxicity potential assessed per ICH M7 (R1) in silico methodology (Derek Nexus v6.2, Sarah Nexus v3.2).

Accelerated stability studies conducted on the formulated lyophilized cake under ICH Q1A (R2) conditions—40°C ± 2°C and 75% ± 5% relative humidity for 6 months—revealed a degradation pathway specific to the thiazole C-2 aminomethyl amide linkage, wherein hydrolysis of the amide bond generates 2,5-dichlorothiophene-3-carboxylic acid as a class 2 genotoxic impurity alert (per ICH M7 DEREK structural alert classification). The rate of degradation follows pseudo-first-order kinetics with a rate constant k = 1.8 × 10⁻³ day⁻¹ at 40°C, corresponding to a t₉₀ (time to 10% degradation) of 58 days. Reformulation with a citrate buffer system (50 mM, pH 4.5) in the reconstitution vehicle suppressed the hydrolysis rate threefold (k = 5.9 × 10⁻⁴ day⁻¹, t₉₀ = 179 days), demonstrating the necessity of controlling the microenvironmental pH of the lyophilized matrix. Residual solvents in the drug substance intermediate are controlled per USP <467> Residual Solvents, with Class 2 solvents DMF and CH₂Cl₂ limited to 880 ppm and 600 ppm respectively; actual batch data from three consecutive commercial-scale campaigns (Campaigns L-014 through L-016) demonstrated DMF at 62-115 ppm and CH₂Cl₂ at 28-41 ppm by headspace GC-FID, comfortably within the concentration limits specified under Option 1 testing.

When Photoredox Catalysis Accesses the C-4 Radical: an Electron-Transfer Platform for Late-Stage Functionalization

Beyond the conventional two-electron cross-coupling manifolds that exploit the polarized C4-Br σ-bond, Methyl 4-Bromo-2-Thiazole Carboxylate has been adopted as a substrate in visible-light-mediated single-electron transfer (SET) protocols, generating a thiazole C-4 radical intermediate that engages in Giese-type conjugate addition and Minisci-type heteroarene functionalization with a distinct chemo- and regioselectivity profile. The optimized protocol employs a dual catalytic system consisting of [Ir(dF(CF₃)ppy)₂(dtbbpy)]PF₆ (1 mol%) as the photoredox catalyst (excited-state reduction potential E*₁/₂ = +1.21 V vs. SCE in MeCN, sufficient to reduce the C4-Br bond with Epc = -1.45 V vs. SCE at a glassy carbon electrode under the same conditions) and NiCl₂·glyme (5 mol%) with 4,4'-di-tert-butyl-2,2'-bipyridine (5.5 mol%) as the organometallic cross-coupling co-catalyst. The reaction is irradiated with a 34 W blue LED lamp (peak emission 450 nm, photon flux 1.8 × 10⁻⁷ einstein/s as determined by ferrioxalate actinometry) in a temperature-controlled reactor maintained at 25°C ± 1°C to prevent thermal background reactions from contributing to conversion. The radical acceptor—representatively benzyl acrylate—is deployed at 1.5 equivalents relative to the thiazole substrate, and the reductant (Tris(trimethylsilyl)silane, TTMSS) is charged at 2.0 equivalents to turnover the nickel catalytic cycle. Under these conditions, the conjugate adduct is obtained in 76% isolated yield after 18 hours of irradiation, with the C-2 methyl ester remaining entirely intact throughout the transformation. This orthogonal reactivity profile—wherein the C-4 position undergoes net alkylation while the C-2 ester survives as a latent synthetic handle for subsequent amidation or hydrolysis—enables a divergent synthetic strategy not accessible via organometallic cross-coupling alone. A documented scale-up of this chemistry to 50 mmol (approx. 11.1 g of Methyl 4-Bromo-2-Thiazole Carboxylate) in a custom-built 250 mL jacketed photoreactor equipped with a coaxial 450 nm LED array (total optical output 95 W, photon flux density at the reactor wall 6.2 mW/cm²) encountered an engineering challenge: the photon penetration depth in the reaction medium, as calculated from the molar extinction coefficient of the Ir(III) photocatalyst (ε = 1,850 M⁻¹cm⁻¹ at 450 nm) and the catalyst loading, yields a 90% photon absorption path length of only 2.8 mm from the irradiated surface, rendering the bulk of the cylindrical reactor volume (> 70% for a 50 mm inner diameter vessel) effectively unilluminated. Resolution required implementation of a flow-chemistry approach: a continuous recirculation loop through a 1.6 mm ID FEP tubing coil (residence time per pass 3.2 minutes at a total flow rate of 5.0 mL/min) wound around the LED light source, achieving a total of 340 passes over the 18-hour batch duration and delivering an isolated yield of 73%—statistically indistinguishable from the 0.5 mmol small-scale result. The photoredox pathway represents a specialized, albeit commercially niche, application of Methyl 4-Bromo-2-Thiazole Carboxylate in the synthesis of highly functionalized thiazole building blocks for medicinal chemistry programs exploring chemical space inaccessible through conventional ground-state reactivity. The finished products of this transduction are typically advanced intermediates (not terminal APIs) that undergo 2-4 additional synthetic transformations before reaching candidate nomination stage; as such, the applicable regulatory framework is that of GMP intermediate production with quality oversight focused on chromatographic purity (≥ 95% by HPLC-UV at 254 nm), residual metal content (Ir ≤ 10 ppm, Ni ≤ 25 ppm by ICP-MS per USP <233>), and structural confirmation by ¹H, ¹³C, and ¹⁹F NMR spectroscopy.